Compare Centrus Energy Corp (LEU) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centrus Energy Corp vs BIO-TECHNE Corp — how do they compare? Centrus Energy Corp trades at $142.44 (market cap $2.91B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 3.9× Centrus Energy Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Centrus Energy Corp for 29 Days and BIO-TECHNE Corp for 64 Days on average.
| LEU | TECH | |
|---|---|---|
Market Cap | $2.91B | $11.36B |
Volume | 903,777 | 5,390,331 |
Sector | Energy | Health |
52-Week High | $436.00 | $72.61 |
52-Week Low | $138.18 | $43.31 |
Typical Hold Time | 29 Days | 64 Days |
Enterprise Value | $2.22B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $142.09, down 3.43% on the day, with technical indicators showing a bearish trend. The company reported mixed quarterly results, missing Q4 2025 EPS estimates but beating in Q1 and Q2 2026. Recent news highlights Centrus as a key player in the nuclear fuel supply chain, securing multiple HALEU contracts amid growing nuclear energy demand. Valuation metrics appear elevated with a P/E of 75.18 and P/S of 6.68, while profitability metrics show a net income margin of 10.23% and ROE of 8.05%.
The outlook for LEU is cautiously optimistic, supported by strategic positioning in the nuclear fuel market and recent contract wins. However, high valuation multiples and recent earnings volatility present risks. Analyst consensus is mixed with 46% buy ratings and a $218.10 price target, suggesting potential upside if execution improves. Key risks include execution challenges, competitive pressures, and dependence on nuclear energy policy support.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, as the stock approaches its 52-week high of $72.70. The company shows strong profitability with 65.77% gross margins and 14.97% net income margin, though earnings have been mixed with one miss and two beats in recent quarters. Technical indicators show a bullish trend with support at $72 and resistance at $73. Recent news highlights shareholder approval of the Merck KGaA acquisition at $73 per share, providing a clear near-term catalyst.
The acquisition premium offers limited upside from current levels, while fundamental metrics show elevated valuation (P/E 62.46) despite solid profitability. Key risks include integration challenges post-acquisition and potential regulatory scrutiny. Analyst consensus leans neutral with 46% buy ratings and a $65.78 price target below current trading levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
